Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
J Mycol Med ; 34(3): 101490, 2024 Jun 04.
Artículo en Inglés | MEDLINE | ID: mdl-38852225

RESUMEN

Due to large outbreaks observed worldwide, Candida auris has emerged as a major threat to healthcare facilities. To prevent these phenomena, a systematic screening should be performed in patients transferred from regions where the pathogen is highly endemic. In this study, we recorded and analyzed French mycologists' current knowledge and practice regarding C. auris screening and diagnosis. Thirty-six centers answered an online questionnaire. Only 11 (30.6 %) participants were aware of any systematic screening for C. auris for patients admitted to their hospital. In the case of post-admission screening, axillae/groins (n = 21), nares (n = 7), rectum (n = 9), and mouth (n = 6) alone or various combinations were the body sites the most frequently sampled. Only six centers (8.3 %) reported using a commercially available plate allowing the differentiation of C. auris colonies from that of other Candida species, while five laboratories (13.8 %) had implemented a C. auris-specific qPCR. Considering the potential impact on infected patients and the risk of disorganization in the care of patients, it is crucial to remember to biologists and clinicians the utmost importance of systematic screening on admission.

2.
J Mycol Med ; 30(2): 100970, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-32334948

RESUMEN

A survey of mycology laboratories for antifungal susceptibility testing (AFST) was undertaken in France in 2018, to better understand the difference in practices between the participating centers and to identify the difficulties they may encounter as well as eventual gaps with published standards and guidelines. The survey captured information from 45 mycology laboratories in France on how they perform AFST (number of strains tested, preferred method, technical and quality aspects, interpretation of the MIC values, reading and interpretation difficulties). Results indicated that 86% of respondents used Etest as AFST method, with a combination of one to seven antifungal agents tested. Most of the participating laboratories used similar technical parameters to perform their AFST method and a large majority used, as recommended, internal and external quality assessments. Almost all the participating mycology laboratories (98%) reported difficulties to interpret the MIC values, especially when no clinical breakpoints are available. The survey highlighted that the current AFST practices in France need homogenization, particularly for MIC reading and interpretation.


Asunto(s)
Antifúngicos/uso terapéutico , Laboratorios , Pruebas de Sensibilidad Microbiana , Micología , Práctica Profesional/estadística & datos numéricos , Pruebas Antimicrobianas de Difusión por Disco/métodos , Pruebas Antimicrobianas de Difusión por Disco/normas , Pruebas Antimicrobianas de Difusión por Disco/estadística & datos numéricos , Farmacorresistencia Fúngica , Francia , Historia del Siglo XXI , Humanos , Laboratorios/normas , Laboratorios/estadística & datos numéricos , Ensayos de Aptitud de Laboratorios/métodos , Ensayos de Aptitud de Laboratorios/estadística & datos numéricos , Pruebas de Sensibilidad Microbiana/métodos , Pruebas de Sensibilidad Microbiana/normas , Pruebas de Sensibilidad Microbiana/estadística & datos numéricos , Micología/historia , Micología/métodos , Micología/normas , Micología/estadística & datos numéricos , Práctica Profesional/normas , Control de Calidad , Encuestas y Cuestionarios
3.
J Clin Pharm Ther ; 43(2): 265-268, 2018 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-28795412

RESUMEN

WHAT IS KNOWN AND OBJECTIVE: Voriconazole and vincristine are major therapeutics in paediatric haematology. However, the risk-benefit ratio of the treatment of invasive aspergillosis with voriconazole in patients receiving vincristine-based chemotherapy remains unclear. CASE DESCRIPTION: We report severe peripheral and central neurological disorders in a 14-year-old girl with T-cell acute lymphoblastic leukaemia and pulmonary aspergillosis. The case describes a strong exacerbation by voriconazole of the vincristine-induced neuropathic pains. It shows the high variability of the trough serum concentration of voriconazole leading to antifungal treatment failure and suggests that its own central neurotoxicity could also be potentiated by vincristine. WHAT IS NEW AND CONCLUSION: Given the risk of either insufficient antifungal efficacy or excessive neurological disorders, this case warns on a probable unfavourable risk-benefit profile of voriconazole during vincristine-based chemotherapy in adolescents.


Asunto(s)
Aspergilosis/tratamiento farmacológico , Enfermedades del Sistema Nervioso/inducido químicamente , Vincristina/efectos adversos , Vincristina/uso terapéutico , Voriconazol/efectos adversos , Voriconazol/uso terapéutico , Adolescente , Antifúngicos/efectos adversos , Antifúngicos/uso terapéutico , Antineoplásicos Fitogénicos/efectos adversos , Antineoplásicos Fitogénicos/uso terapéutico , Femenino , Humanos , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico
4.
Antimicrob Agents Chemother ; 60(8): 5088-91, 2016 08.
Artículo en Inglés | MEDLINE | ID: mdl-27297480

RESUMEN

In vitro susceptibility of 933 Candida isolates, from 16 French hospitals, to micafungin was determined using the Etest in each center. All isolates were then sent to a single center for determination of MICs by the EUCAST reference method. Overall essential agreement between the two tests was 98.5% at ±2 log2 dilutions and 90.2% at ±1 log2 dilutions. Categorical agreement was 98.2%. The Etest is a valuable alternative to EUCAST for the routine determination of micafungin MICs in medical mycology laboratories.


Asunto(s)
Antifúngicos/farmacología , Candida/efectos de los fármacos , Equinocandinas/farmacología , Lipopéptidos/farmacología , Candida/genética , Farmacorresistencia Fúngica/genética , Micafungina , Pruebas de Sensibilidad Microbiana
5.
Clin Microbiol Infect ; 22(9): 810.e1-810.e8, 2016 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-26706615

RESUMEN

The main objective of this study was to assess the diagnostic performance of a set of three Mucorales quantitative PCR assays in a retrospective multicentre study. Mucormycosis cases were recorded thanks to the French prospective surveillance programme (RESSIF network). The day of sampling of the first histological or mycological positive specimen was defined as day 0 (D0). Detection of circulating DNA was performed on frozen serum samples collected from D-30 to D30, using quantitative PCR assays targeting Rhizomucor, Lichtheimia, Mucor/Rhizopus. Forty-four patients diagnosed with probable (n = 19) or proven (n = 25) mucormycosis were included. Thirty-six of the 44 patients (81%) had at least one PCR-positive serum. The first PCR-positive sample was observed 9 days (range 0-28 days) before diagnosis was made using mycological criteria and at least 2 days (range 0-24 days) before imaging. The identifications provided with the quantitative PCR assays were all concordant with culture and/or PCR-based identification of the causal species. Survival rate at D84 was significantly higher for patients with an initially positive PCR that became negative after treatment initiation than for patients whose PCR remained positive (48% and 4%, respectively; p <10-6). The median time for complete negativity of PCR was 7 days (range 3-19 days) after initiation of l-AmB treatment. Despite some limitations due to the retrospective design of the study, we showed that Mucorales quantitative PCR could not only confirm the mucormycosis diagnosis when other mycological arguments were present but could also anticipate this diagnosis. Quantification of DNA loads may also be a useful adjunct to treatment monitoring.


Asunto(s)
ADN de Hongos , Mucorales/genética , Mucormicosis/diagnóstico , Mucormicosis/microbiología , Anciano , Anciano de 80 o más Años , Comorbilidad , ADN de Hongos/sangre , Femenino , Francia/epidemiología , Fungemia , Humanos , Masculino , Persona de Mediana Edad , Mucormicosis/epidemiología , Mucormicosis/terapia , Vigilancia de la Población , Estudios Retrospectivos , Análisis de Supervivencia
7.
Med Trop (Mars) ; 67(2): 175-8, 2007 Apr.
Artículo en Francés | MEDLINE | ID: mdl-17691438

RESUMEN

The purpose of this report is to describe a case of febrile hypereosinophilic syndrome in a traveler three weeks after returning from a sightseeing trip to Guinea. Laboratory testing demonstrated an inflammatory response syndrome and hepatic cytolysis. Parasite serology led to suspicion of toxocariasis that was treated using albendazole. Follow-up tests at two months showed the presence of Schistosoma mansoni eggs in stools despite negative standard serodiagnostic testing (hemagglutination). Secondarily Western blot testing of serum samples at one, two and 14 months after returning from Guinea continued to show only protein bands specific to toxocariasis with no bands specific to bilhariziasis. These findings provide further evidence of the limitations of serological testing for detection of bilharziasis in travelers and the difficulty of diagnosis. Guinea is a high-risk tourist destination. Intestinal and urinary bilharziasis are endemic over three-fourths of country. Travelers planning even short stays in areas where bilharziasis is endemic should be advised on preventive measures.


Asunto(s)
Errores Diagnósticos , Síndrome Hipereosinofílico/parasitología , Esquistosomiasis mansoni/diagnóstico , Viaje , Animales , Western Blotting , Ensayo de Inmunoadsorción Enzimática , Heces/parasitología , Guinea , Pruebas de Hemaglutinación , Humanos , Masculino , Persona de Mediana Edad , Schistosoma mansoni/aislamiento & purificación , Esquistosomiasis mansoni/sangre
8.
Eur J Clin Microbiol Infect Dis ; 21(10): 748-50, 2002 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-12415475

RESUMEN

In order to compare the performances of a specific fungal medium and a standard aerobic medium for detecting growth of Fusarium spp. in blood, simulated blood cultures were performed. For lower inocula (10(2) and 10(3) cfu/ml taken together), fungal growth was detected significantly earlier using the fungal medium. The mean difference in the time to detection between the two media was 22.33 h at 10(2) cfu/ml, with the maximum difference being achieved for Fusarium verticilloides at 37.05 h. These in vitro test results suggest fungal medium could be useful for obtaining more rapid blood culture results when evaluating patients at risk for invasive infection with Fusarium spp.


Asunto(s)
Sangre/microbiología , Medios de Cultivo Condicionados/normas , Fungemia/microbiología , Fusarium/crecimiento & desarrollo , Micosis/microbiología , Técnicas de Tipificación Bacteriana , Fusarium/clasificación , Humanos , Micología/métodos , Sensibilidad y Especificidad
9.
Clin Infect Dis ; 35(11): 1360-7, 2002 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-12439799

RESUMEN

Trichoderma species are filamentous fungi that were previously considered to be culture contaminants. We report 2 well-documented cases of invasive Trichoderma infections, and we comprehensively review the literature on this topic. Trichoderma species are mainly responsible for continuous ambulatory peritoneal dialysis-associated peritonitis (7 cases) and invasive infections in immunocompromised patients (9 cases) with a hematologic malignancy or solid-organ transplant. Definitive diagnosis is difficult to achieve because of the lack of specific diagnosis tools. Species identification can benefit from a molecular approach. Trichoderma longibrachiatum is the most common species involved in these infections. Regardless of the type of infection, the prognosis was poor, with 8 deaths among 18 cases. This may be partially because of the resistance of these organisms to the majority of available antifungal agents, including amphotericin B. Trichoderma species now should be added to the growing list of emerging filamentous fungal pathogens.


Asunto(s)
Antifúngicos/farmacología , Farmacorresistencia Microbiana/fisiología , Micosis/microbiología , Trichoderma/efectos de los fármacos , Adulto , Anciano , Anciano de 80 o más Años , Niño , Femenino , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Micosis/mortalidad
11.
Pathol Biol (Paris) ; 43(4): 320-3, 1995 Apr.
Artículo en Francés | MEDLINE | ID: mdl-7567123

RESUMEN

Antibiotic susceptibility of 948 bacterial strains isolated from varied samples essentially proceeding from urinary infections in five Paris psychiatric Hospitals was determined by disk diffusion method. E. coli, P. mirabilis, Klebsiella spp., P. aeruginosa et S. aureus are the predominant bacteria. 40% of S. aureus are methicilline resistant. Enterobacteriaceae are progressively becoming resistant to aminopenicillines, but remain sensitive to third generation cephalosporines. They are still susceptible to first generation quinolones. At least, if no resistance of P. aeruginosa to imipeneme has been reported, 30% of strains are resistant to ciprofloxacine. Resistance phenotypes to antibiotics of the strains isolated in patients from psychiatric Hospitals are located between those observed in out patients and in patients from general Hospitals. However, we noticed a worrying evolution of resistance to those encontered in psychiatric Hospitals. Therefore, a multiresistant strains emergence monitoring must be carried out regulary.


Asunto(s)
Escherichia coli/aislamiento & purificación , Klebsiella/aislamiento & purificación , Proteus mirabilis/aislamiento & purificación , Staphylococcus aureus/aislamiento & purificación , Infecciones Urinarias/microbiología , 4-Quinolonas , Antibacterianos/farmacología , Antiinfecciosos/farmacología , Farmacorresistencia Microbiana , Escherichia coli/efectos de los fármacos , Hospitales Psiquiátricos , Humanos , Técnicas In Vitro , Klebsiella/efectos de los fármacos , Fenotipo , Proteus mirabilis/efectos de los fármacos , Pseudomonas aeruginosa/efectos de los fármacos , Pseudomonas aeruginosa/aislamiento & purificación , Staphylococcus aureus/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA